Search

  3. ProQR Appoints David M. Rodman, MD as Chief Development Strategy Officer

    Press release

    … ProQR Appoints David M. Rodman, MD as Chief Development … the Netherlands, March 27, 2017 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR) today announced that it … of RNA approaches to treating disease.” said Noreen R. Henig, MD, Chief Medical Officer. “There are very few …

  5. ProQR Appoints Yi-Tao Yu, Ph.D., to Its Scientific Advisory Board

    Press release

    LEIDEN, the Netherlands, May 23, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the treatment of severe genetic rare diseases, today announced the appointment of Dr.

  6. ProQR Receives Rare Pediatric Disease Designation from FDA for QR-421a

    Press release

    … ProQR Receives Rare Pediatric Disease Designation from FDA … & CAMBRIDGE, Mass., Jan. 30, 2020 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to … said Daniel A. de Boer, chief executive officer of ProQR. “Both sepofarsen for LCA10, the most common cause of …